AN2 Therapeutics Inc (ANTX)
2.23
+0.12
(+5.69%)
USD |
NASDAQ |
Jun 27, 16:00
2.24
+0.01
(+0.45%)
After-Hours: 20:00
AN2 Therapeutics SG&A Expense (Quarterly): 3.641M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 3.641M |
December 31, 2023 | 3.896M |
September 30, 2023 | 3.751M |
June 30, 2023 | 3.063M |
March 31, 2023 | 4.054M |
December 31, 2022 | 3.724M |
September 30, 2022 | 3.342M |
Date | Value |
---|---|
June 30, 2022 | 3.635M |
March 31, 2022 | 2.05M |
December 31, 2021 | 1.782M |
September 30, 2021 | 1.587M |
June 30, 2021 | 0.898M |
March 31, 2021 | 0.401M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.401M
Minimum
Mar 2021
4.054M
Maximum
Mar 2023
2.756M
Average
3.342M
Median
Sep 2022
SG&A Expense (Quarterly) Benchmarks
Revance Therapeutics Inc | 68.91M |
Aquestive Therapeutics Inc | 10.69M |
Humacyte Inc | 5.314M |
NovaBay Pharmaceuticals Inc | 3.346M |
Palatin Technologies Inc | 2.033M |